Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families

Hereditary Cancer in Clinical Practice

Jan Lubiński¹  Pablo Serrano-Fernandez¹  Cezary Cybulski¹  Katarzyna Paszkowska-Szczur¹  Bohdan Górski¹  Dagmara Dymerska¹  Grzegorz Kurzawski¹  Tomasz Byrski¹  Tomasz Huzarski¹  Jacek Gronwald¹  Rodney J Scott²  Tomasz Gromowski¹  Tadeusz Dębniak¹ 

[1] Department o f Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland;Discipline of Medical Genetics, Faculty of Health, University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia

关键词: Adnexectomy;    Endometrial cancer;    Ovarian cancer;    Lynch syndrome;    HNPCC;   

Others  :  1133772
DOI  :  10.1186/s13053-015-0025-2

 received in 2014-10-01, accepted in 2015-01-05,  发布年份 2015

【 摘 要 】

Background

Over half the cancer deaths in HNPCC families are due to extra-colonic malignancies that include endometrial and ovarian cancers. The benefits of surveillance for gynecological cancers are not yet proven and there is no consensus on the optimal surveillance recommendations for women with MMR mutations.

Methods

We performed a systematic review of the literature and evaluated gynecological cancer risk in a series of 631 Polish HNPCC families classified into either Lynch Syndrome (LS, MMR mutations detected) or HNPCC (fulfillment of the Amsterdam or modified Amsterdam criteria).

Results

Published data clearly indicates no benefit for ovarian cancer screening in contrast to risk reducing surgery.

We confirmed a significantly increased risk of OC in Polish LS families (OR = 4,6, p < 0.001) and an especially high risk of OC was found for women under 50 years of age: OR = 32,6, p < 0.0001 (95% CI 12,96-81,87). The cumulative OC risk to 50 year of life was calculated to be 10%. Six out of 19 (32%) early-onset patients from LS families died from OC within 2 years of diagnosis. We confirmed a significantly increased risk of EC (OR = 26, 95% CI 11,36-58,8; p < 0,001). The cumulative risk for EC in Polish LS families was calculated to be 67%.

Conclusions

Due to the increased risk of OC and absence of any benefit from gynecological screening reported in the literature it is recommended that prophylactic oophorectomy for female carriers of MMR mutations after 35 year of age should be considered as a risk reducing option. Annual transvaginal ultrasound supported by CA125 or HE4 marker testing should be performed after prophylactic surgery in these women.

Due to the high risk of EC it is reasonable to offer, after the age of 35 years, annual clinical gynecologic examinations with transvaginal ultrasound supported by routine aspiration sampling of the endometrium for women from either LS or HNPCC families. An alternative option, which could be taken into consideration for women preferring surgical prevention, is risk reducing total hysterectomy (with bilateral salpingo-oophorectomy) for carriers after childbearing is complete.

【 授权许可】

   
2015 Debniak et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Aaltonen L, Johns L, Järvinen H, Mecklin JP, Houlston R: Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res 2007, 13:356-61.
• [2]Aarnio M: Clinicopathological features and management of cancers in lynch syndrome. Patholog Res Int. 2012, 12:1-6.
• [3]Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al.: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75:1027-38.
• [4]Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al.: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993, 75:1215-25.
• [5]Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al.: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994, 371:75-80.
• [6]Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, et al.: Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263:1625-9.
• [7]Tutlewska K, Lubinski J, Kurzawski G: Germline deletions in the EPCAM gene as a cause of Lynch syndrome - literature review. Hered Cancer Clin Pract 2013, 11:9. BioMed Central Full Text
• [8]Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 2003, 348:919-32.
• [9]Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, et al.: The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008, 123:444-9.
• [10]Lin-Hurtubise KM, Yheulon CG, Gagliano RA Jr, Lynch HT: Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1. J Surg Oncol 2013, 108:433-7.
• [11]Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al.: Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013, 62:812-23.
• [12]Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al.: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118:829-34.
• [13]Pylvänäinen K, Lehtinen T, Kellokumpu I, Järvinen H, Mecklin JP: Causes of death of mutation carriers in Finnish Lynch syndrome families. Fam Cancer 2012, 11:467-71.
• [14]Wojciechowska U, Didkowska J, Zatoński W: Cancer in Poland in 2010. The Maria-Skłodowska-Curie Memorial Cancer Center, Department of Epidemiology and cancer Prevention, Polish National Cancer Registry, Warsaw; 2012.
• [15]Pande M, Wei C, Chen J, Amos CI, Lynch PM, Lu KH, et al.: Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry. Fam Cancer 2012, 11:441-7.
• [16]Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al.: Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012, 30:4409-15.
• [17]Watson P, Bützow R, Lynch HT, Mecklin JP, Järvinen HJ, Vasen HF, et al.: The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001, 82:223-8.
• [18]Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al.: Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005, 129:415-21.
• [19]Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, et al.: Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009, 75:141-9.
• [20]Stuckless S, Parfrey PS, Woods MO, Cox J, Fitzgerald GW, Green JS, et al.: The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome. Fam Cancer 2007, 6:1-12.
• [21]Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995, 64:430-3.
• [22]Quehenberger F, Vasen HF, van Houwelingen HC: Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005, 42:491-6.
• [23]Ketabi Z, Gerdes AM, Mosgaard B, Ladelund S, Bernstein I: The results of gynecologic surveillance in families with hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2014, 133:526-30.
• [24]Auranen A, Joutsiniemi T: A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 2011, 90:437-44.
• [25]Barrow PJ, Ingham S, O’Hara C, Green K, McIntyre I, Lalloo F, et al.: The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 2013, 12:57-63.
• [26]Rodriguez-Bigas MA, Möeslein G: Surgical treatment of hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome). Fam Cancer 2013, 12:295-300.
• [27]Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, et al.: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004, 127:17-25.
• [28]Crijnen TE, Janssen-Heijnen ML, Gelderblom H, Morreau J, Nooij MA, Kenter GG, et al.: Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005, 4:301-5.
• [29]Grindedal EM, Renkonen-Sinisalo L, Vasen H, Evans G, Sala P, Blanco I, et al.: Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. J Med Genet 2010, 47:99-102.
• [30]Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, et al.: The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. Am J Surg Pathol 2014, 38:1173-81.
• [31]Niskakoski A, Kaur S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, et al.: Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas. Int J Cancer 2013, 133:2596-608.
• [32]Karlan BY, Platt LD: Ovarian cancer screening. The role of ultrasound in early detection. Cancer 1995, 76:2011-5.
• [33]Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al.: Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006, 296:1507-17.
• [34]Schmeler KM, Lu KH: Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl Oncol 2008, 10:313-7.
• [35]Meyer LA, Broaddus RR, Lu KH: Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009, 16:14-22.
• [36]Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J: Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumour Biol 2014, 35:6127-38.
• [37]Ghasemi N, Ghobadzadeh S, Zahraei M, Mohammadpour H, Bahrami S, Ganje MB, et al.: HE4 combined with CA125: favorable screening tool for ovarian cancer. Med Oncol 2014, 31:808.
• [38]Gerritzen LH, Hoogerbrugge N, Oei AL, Nagengast FM, van Ham MA, Massuger LF, et al.: Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Fam Cancer 2009, 8:391-7.
• [39]Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG: Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003, 91:74-80.
• [40]Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF, et al.: The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002, 94:1708-12.
• [41]Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ: Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007, 120:821-4.
• [42]Stuckless S, Green J, Dawson L, Barrett B, Woods MO, Dicks E, et al.: Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. Clin Genet 2013, 83:359-64.
• [43]Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al.: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006, 354:261-9.
• [44]Yang KY, Caughey AB, Little SE, Cheung MK, Chen LM: A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families. Fam Cancer 2011, 10:535-43.
• [45]Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, et al.: Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 2008, 113:326-35.
• [46]Chen LM, Yang KY, Little SE, Cheung MK, Caughey AB: Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 2007, 110:18-25.
• [47]Schmeler KM, Daniels MS, Soliman PT, Broaddus RR, Deavers MT, Vu TM, et al.: Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 2010, 115:432-4.
• [48]Ghezzi F, Uccella S, Cromi A, Bogani G, Donadello N, Riva C: Primary peritoneal cancer in Lynch syndrome: a clinical-pathologic report of a case and analysis of the literature. Int J Gynecol Pathol 2013, 32:163-6.
• [49]Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engel J Med 2002, 346:1616-22.
• [50]Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609-15.
• [51]Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al.: Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014, 32:1547-53.
• [52]Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008, 26:20-5.
• [53]Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al.: “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008, 26:5530-6.
• [54]Marcelis CL, van der Putten HW, Tops C, Lutgens LC, Moog U: Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation? Fam Cancer 2001, 1:107-9.
• [55]Lécuru F, Le Frère Belda MA, Bats AS, Tulpin L, Metzger U, Olschwang S, et al.: Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. Int J Gynecol Cancer 2008, 18:1326-31.
• [56]Manchanda R, Saridogan E, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, et al.: Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet 2012, 286:1555-62.
• [57]Helder-Woolderink JM, De Bock GH, Sijmons RH, Hollema H, Mourits MJ: The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome. Gynecol Oncol 2013, 131:304-8.
• [58]Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP: The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000, 89:1765-72.
• [59]Huang M, Sun C, Boyd-Rogers S, Burzawa J, Milbourne A, Keeler E, et al.: Prospective study of combined colon and endometrial cancer screening in women with lynch syndrome: a patient-centered approach. J Oncol Pract 2011, 7:43-7.
• [60]Lu KH, Daniels M: Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer 2013, 12:273-7.